Unknown

Dataset Information

0

EGFR-targeting, ?-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.


ABSTRACT: Defensins play an essential role in innate immunity. In this study, a novel recombinant ?-defensin that targets the epidermal growth factor receptor (EGFR) was designed and prepared. The EGFR-targeting ?-defensin consists of an EGF-derived oligopeptide (Ec), a ?-defensin-1 peptide (hBD1) and a lidamycin-derived apoprotein (LDP), which serves as the "scaffold" for the fusion protein (Ec-LDP-hBD1). Ec-LDP-hBD1 effectively bound to EGFR highly expressed human epidermoid carcinoma A431 cells. The cytotoxicity of Ec-LDP-hBD1 to EGFR highly expressed A431 cells was more potent than that to EGFR low-expressed human lung carcinoma A549 and H460 cells (the IC50 values in A431, A549, and H460 cells were 1.8?±?0.55, 11.9?±?0.51, and 5.19?±?1.21??mol/L, respectively); in addition, the cytotoxicity of Ec-LDP-hBD1 was much stronger than that of Ec-LDP and hBD1. Moreover, Ec-LDP-hBD1 suppressed cancer cell proliferation and induced mitochondria-mediated apoptosis. Its in vivo anticancer action was evaluated in athymic mice with A431 and H460 xenografts. The mice were administered Ec-LDP-hBD1 (5, 10?mg/kg, i.v.) two times with a weekly interval. Administration of Ec-LDP-hBD1 markedly inhibited the tumor growth without significant body weight changes. The in vivo imaging further revealed that Ec-LDP-hBD1 had a tumor-specific distribution with a clear image of localization. The results demonstrate that the novel recombinant EGFR-targeting ?-defensin Ec-LDP-hBD1 displays both selectivity and enhanced cytotoxicity against relevant cancer cells by inducing mitochondria-mediated apoptosis and exhibits high therapeutic efficacy against the EGFR-expressed carcinoma xenograft. This novel format of ?-defensin, which induces mitochondrial-mediated apoptosis, may play an active role in EGFR-targeting cancer therapy.

SUBMITTER: Liu WJ 

PROVIDER: S-EPMC6289343 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

EGFR-targeting, β-defensin-tailored fusion protein exhibits high therapeutic efficacy against EGFR-expressed human carcinoma via mitochondria-mediated apoptosis.

Liu Wen-Juan WJ   Liu Xiu-Jun XJ   Xu Jian J   Li Liang L   Li Yi Y   Zhang Sheng-Hua SH   Wang Jia-Lin JL   Miao Qing-Fang QF   Zhen Yong-Su YS  

Acta pharmacologica Sinica 20180716 11


Defensins play an essential role in innate immunity. In this study, a novel recombinant β-defensin that targets the epidermal growth factor receptor (EGFR) was designed and prepared. The EGFR-targeting β-defensin consists of an EGF-derived oligopeptide (Ec), a β-defensin-1 peptide (hBD1) and a lidamycin-derived apoprotein (LDP), which serves as the "scaffold" for the fusion protein (Ec-LDP-hBD1). Ec-LDP-hBD1 effectively bound to EGFR highly expressed human epidermoid carcinoma A431 cells. The cy  ...[more]

Similar Datasets

| S-EPMC5321462 | biostudies-literature
| S-EPMC7686653 | biostudies-literature
| S-EPMC4026085 | biostudies-other
| S-EPMC5537225 | biostudies-literature
| S-EPMC2816690 | biostudies-literature
| S-EPMC6414722 | biostudies-literature
| S-EPMC9783122 | biostudies-literature
| S-EPMC4474171 | biostudies-literature
| S-EPMC4740463 | biostudies-literature
| S-EPMC8137984 | biostudies-literature